ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1247

A Pilot Evaluation of Thiol Metabolome in Peritoneal Dialysate as an Indicator of Peritoneal Fibrosis

Session Information

Category: Dialysis

  • 703 Dialysis: Peritoneal Dialysis

Authors

  • Branco, Patricia Quadros, Santa Cruz Hospital/CHLO, Lisbon, Portugal
  • Martins, Ana Rita Mateus, Santa Cruz Hospital/CHLO, Lisbon, Portugal
  • Coelho, Rita Alexandre, Centro Estudos Doenças Crónicas, Lisboa, Portugal
  • Pinto, Daniel G., Centro Hospitalar Lisboa Ocidental, Lisboa, Portugal
  • Mateus, Catarina, Santa Cruz Hospital/CHLO, Lisbon, Portugal
  • Calça, Rita, Santa Cruz Hospital/CHLO, Lisbon, Portugal
  • Sequeira, Catarina Oliveira, Centro Estudos Doenças Crónicas, Lisboa, Portugal
  • Morello, Judit, Centro Estudos Doenças Crónicas, Lisboa, Portugal
  • Pereira, Sofia Azeredo, Centro Estudos Doenças Crónicas, Lisboa, Portugal
Background

The peritoneal dialysate is a precious source to find out markers for a better management of intraperitoneal dialysis (IPD). Low molecular weight thiols have been implied in the epithelial to mesenchymal transition, a process known to occur in peritoneal fibrosis.
This study aimed to evaluate thiol metabolome in peritoneal dialysate and its relationship with peritoneal fibrosis. Thiol metabolome definition: total, free and protein bound fractions of glutathione, cysteine, cysteinylglycine and glutamylcysteine.

Methods

Peritoneal fibrosis was evaluated in biopsy specimen, performed during the placement of Tenkhoff catheter. Histological analysis were performed according to standard methods. Thiol related metabolome in peritoneal dialysate was assessed by high performance liquid chromatography+fluorescence detection. The relation thiol metabolome/fibrosis were assessed by multivariate analysis including principal component analysis (PCA) and partial least squared discriminanting analysis (PLS-DA).

Results

42 patients (26 males), fibrosis in 26%, 16 Diabetic
Age, diabetes, body max index, residual diuresis, Kt/v,nPCR, D/P, GFR residual, peritoneal Ca125, did not influence the thiol metabolome, that differed among those with and without fibrosis (fig). PLS-DA (p=8.09x10-7) identified that among the several thiol fractions obtained, cysteine fractions mainly contributed to this difference.

Conclusion

There is a thiol metabolome profile that can be measured in intraperitoneal dialysate fluid, that is related to fibrosis and rich in oxidized cysteine. This pilot analyses shows the potential contribution of thiol metabolome profile for precision prescription in IPD and stratification of patients according to fibrosis risk. This preliminary data might also support the existence of cysteine-dependent mechanisms of intraperitoneal fibrosis.